ResMed (RMD) Competitors $247.93 +3.01 (+1.23%) (As of 11:27 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RMD vs. BSX, MDT, BDX, EW, IDXX, DXCM, STE, PODD, HOLX, and BAXShould you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), and Baxter International (BAX). These companies are all part of the "health care equipment" industry. ResMed vs. Boston Scientific Medtronic Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories DexCom STERIS Insulet Hologic Baxter International ResMed (NYSE:RMD) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings. Does the media refer more to RMD or BSX? In the previous week, Boston Scientific had 2 more articles in the media than ResMed. MarketBeat recorded 27 mentions for Boston Scientific and 25 mentions for ResMed. ResMed's average media sentiment score of 1.08 beat Boston Scientific's score of 0.95 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 18 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Boston Scientific 20 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of RMD or BSX? 55.0% of ResMed shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 0.5% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is RMD or BSX more profitable? ResMed has a net margin of 23.15% compared to Boston Scientific's net margin of 11.26%. ResMed's return on equity of 25.53% beat Boston Scientific's return on equity.Company Net Margins Return on Equity Return on Assets ResMed23.15% 25.53% 17.59% Boston Scientific 11.26%17.23%9.52% Which has more volatility & risk, RMD or BSX? ResMed has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Do analysts rate RMD or BSX? ResMed currently has a consensus price target of $225.70, suggesting a potential downside of 7.81%. Boston Scientific has a consensus price target of $93.39, suggesting a potential upside of 3.27%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than ResMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ResMed 1 Sell rating(s) 5 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.50Boston Scientific 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.91 Which has better earnings and valuation, RMD or BSX? Boston Scientific has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioResMed$4.69B7.67$1.02B$7.5532.43Boston Scientific$14.24B9.36$1.59B$1.2174.74 Does the MarketBeat Community favor RMD or BSX? Boston Scientific received 612 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 69.55% of users gave Boston Scientific an outperform vote while only 52.73% of users gave ResMed an outperform vote. CompanyUnderperformOutperformResMedOutperform Votes42552.73% Underperform Votes38147.27% Boston ScientificOutperform Votes103769.55% Underperform Votes45430.45% SummaryBoston Scientific beats ResMed on 12 of the 18 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get ResMed News Delivered to You Automatically Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RMD vs. The Competition Export to ExcelMetricResMedSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$35.94B$4.45B$5.31B$20.36BDividend Yield0.85%43.03%5.23%3.45%P/E Ratio32.4325.90136.9744.58Price / Sales7.6752.031,455.4620.33Price / Cash26.9955.4241.6722.41Price / Book6.926.307.334.76Net Income$1.02B$13.60M$117.74M$984.70M7 Day Performance-2.06%2.64%3.38%0.64%1 Month Performance0.23%7.38%2.50%6.66%1 Year Performance53.36%46.32%35.96%24.58% ResMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RMDResMed4.875 of 5 stars$247.93+1.2%$225.70-9.0%+53.4%$36.40B$4.69B32.849,980Positive NewsBSXBoston Scientific4.7091 of 5 stars$90.47-0.2%$93.39+3.2%+61.1%$133.34B$14.24B74.9348,000Short Interest ↓MDTMedtronic4.9529 of 5 stars$86.39-0.2%$95.27+10.3%+8.2%$110.78B$32.36B26.3995,000Positive NewsBDXBecton, Dickinson and Company4.9824 of 5 stars$223.04+0.5%$283.00+26.9%-6.5%$64.47B$20.18B37.3673,000Analyst RevisionPositive NewsEWEdwards Lifesciences4.6717 of 5 stars$70.06-1.8%$77.25+10.3%+3.2%$41.32B$6.00B10.1319,800Analyst ForecastShort Interest ↓IDXXIDEXX Laboratories4.993 of 5 stars$426.72+1.2%$546.56+28.1%-10.7%$34.94B$3.66B40.6711,000Analyst ForecastPositive NewsDXCMDexCom4.9866 of 5 stars$77.99-0.1%$104.59+34.1%-32.0%$30.46B$3.62B46.709,600Positive NewsSTESTERIS4.9733 of 5 stars$219.82+0.3%$253.00+15.1%+7.5%$21.70B$5.33B49.9018,179Analyst RevisionPositive NewsPODDInsulet4.451 of 5 stars$266.78-0.1%$253.27-5.1%+38.7%$18.71B$1.98B45.683,000Positive NewsHOLXHologic4.9045 of 5 stars$79.50+0.1%$89.91+13.1%+11.0%$18.47B$4.03B23.876,990BAXBaxter International4.0408 of 5 stars$33.65-0.2%$40.91+21.6%-8.2%$17.18B$14.81B168.5660,000Short Interest ↑ Related Companies and Tools Related Companies Boston Scientific Competitors Medtronic Competitors Becton, Dickinson and Company Competitors Edwards Lifesciences Competitors IDEXX Laboratories Competitors DexCom Competitors STERIS Competitors Insulet Competitors Hologic Competitors Baxter International Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:RMD) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ResMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
